Buy Rating for PTC Therapeutics Bolstered by Positive Regulatory Prospects and Gene Therapy Advances
PTC Therapeutics Analyst Ratings
PTC Therapeutics (PTCT) Receives a Hold From RBC Capital
Buy Rating Affirmed for PTC Therapeutics Amid Promising Regulatory Progress and Market Opportunity
PTC Therapeutics Analyst Ratings
RBC Raises Price Target on PTC Therapeutics to $28 From $22, Keeps Sector Perform Rating
Positive Outlook for PTC Therapeutics: A Comprehensive Buy Rating Justification
Downgrade to Sell: PTC Therapeutics Faces Significant Commercial and Competitive Challenges
Analysts' Opinions Are Mixed on These Healthcare Stocks: BioLife Solutions (BLFS), Cooper Co (COO) and PTC Therapeutics (PTCT)
Barclays Keeps Their Hold Rating on PTC Therapeutics (PTCT)
PTC Therapeutics: Hold Rating Amidst Revenue Downturn and Regulatory Hurdles
PTC Therapeutics Analyst Ratings
RBC Cuts Price Target on PTC Therapeutics to $22 From $27 Amid Negative Opinion on Translarna From European Medicines Agency Committee; Sector Perform Kept
RBC Capital Keeps Their Hold Rating on PTC Therapeutics (PTCT)
Recommendation to Sell: PTC Therapeutics Faces Market Withdrawal and Increased Competition
William Blair Sticks to Its Buy Rating for PTC Therapeutics (PTCT)
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Regeneron (REGN) and Pediatrix Medical Group (MD)
PTC Therapeutics Faces Headwinds: Sell Rating Justified by Underperformance and Market Challenges
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Regeneron (REGN)
RBC Capital Keeps Their Hold Rating on PTC Therapeutics (PTCT)
No Data